These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2931046)

  • 1. Open, prospective study of the clinical efficacy of ciprofloxacin.
    Ramirez CA; Bran JL; Mejia CR; Garcia JF
    Antimicrob Agents Chemother; 1985 Jul; 28(1):128-32. PubMed ID: 2931046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciprofloxacin: an update on clinical experience.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
    Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin: an overview and prospective appraisal.
    Neu HC
    Am J Med; 1987 Apr; 82(4A):395-404. PubMed ID: 3578329
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections.
    Sanders WE
    Rev Infect Dis; 1988; 10(3):528-43. PubMed ID: 3293158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.
    Eron LJ; Harvey L; Hixon DL; Poretz DM
    Antimicrob Agents Chemother; 1985 Aug; 28(2):308-10. PubMed ID: 2939795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of clinical experience with ciprofloxacin.
    Ball AP
    Eur J Clin Microbiol; 1986 Apr; 5(2):214-9. PubMed ID: 3013631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
    Modai J
    Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, phase IV evaluation of intravenous ciprofloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infections.
    Pankey GA
    Clin Ther; 1995; 17(3):353-65. PubMed ID: 7585840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.
    Saavedra S; Ramírez-Ronda CH; Nevárez M
    Eur J Clin Microbiol; 1986 Apr; 5(2):255-7. PubMed ID: 2941296
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Giamarellou H; Galanakis N; Dendrinos C; Stefanou J; Daphnis E; Daikos GK
    Eur J Clin Microbiol; 1986 Apr; 5(2):232-5. PubMed ID: 2941288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections.
    Mouton Y; Chidiac C; Humbert G; Leroy J; Veyssier P; Modai J; Bertrand A; Dellamonica P; Micoud M; Stahl JP
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():133-40. PubMed ID: 8150757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.
    Mehtar S; Drabu Y; Blakemore P
    Eur J Clin Microbiol; 1986 Apr; 5(2):248-51. PubMed ID: 2941293
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-dosage cefepime as treatment for serious bacterial infections.
    Giamarellou H
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with ciprofloxacin in the USA.
    Arcieri G; August R; Becker N; Doyle C; Griffith E; Gruenwaldt G; Heyd A; O'Brien B
    Eur J Clin Microbiol; 1986 Apr; 5(2):220-5. PubMed ID: 2941286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ciprofloxacin therapy in severe infections.
    Gudiol F; Cabellos C; Pallares R; Linares J; Ariza J
    Am J Med; 1989 Nov; 87(5A):221S-224S. PubMed ID: 2589364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of serious infections with intravenous ciprofloxacin.
    Scully BE; Neu HC
    Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.